

Brain & Behavior Research Foundation

INTERNATIONAL AWARDS DINNER

2024

FRIDAY, OCTOBER 25TH

The Pierre

Celebrating our

Pardes Humanitarian Prizewinners and
Outstanding Achievement Prizewinners

WELCOME



Welcome to the Brain & Behavior Research Foundation's 2024 International Awards Dinner.

Bestowed annually since 2014 and named for the founding President of the BBRF Scientific Council, Dr. Herbert Pardes, the Pardes Humanitarian Prize in Mental Health recognizes a person(s) or organization whose humanitarian work is transformative and of great magnitude, changing the lives and bringing the joy of living to those facing challenges to mental health.

This year's Pardes Prize honors Franca Ma-ih Sulem Yong, a Cameroonian Creative Art Therapist/Psychologist who is known for her advocacy to promote tolerance, forgiveness, mental health and human fraternity as keys to sustainable peace.

The 2024 Honorary Pardes Prize is being awarded to the Graham Boeckh Foundation for serving as a catalyst for transformational changes that significantly improve the lives of people living with, or at risk of, mental illness.

Also, this evening we will honor six innovative and exceptional scientists for their contributions to the advancement of the treatment and understanding of schizophrenia, bipolar disorder, pediatric mood and anxiety disorders, and cognitive neuroscience. Their work is distinguished by their use of cutting-edge technologies and devotion to finding innovative new therapies that will improve care for those living with mental illness, as well as their efforts to seek preventive and diagnostic tools for the future. Our Outstanding Achievement Prizewinners are selected by special committees of the BBRF's Scientific Council.

Earlier today they each spoke at the BBRF International Mental Health Research Symposium on topics that included: identifying risk factors for psychosis prior to the first appearance of symptoms; a cognitive neuroscience approach to understanding circuits and symptoms in psychosis; exploration of mechanisms in breakthrough rapid-acting therapies for mood disorders; and the investigation of differences in early social development in relation to their clinical and translational implications.

This year we are delighted to be celebrating the 25th anniversary of the Ruane Prize for Outstanding Achievement in Child & Adolescent Psychiatric Research. We thank The Carmel Hill Fund who have been generously funding this Prize since its inception.

We are delighted you have joined us to celebrate the progress being made in brain and behavior research. Our shared commitment to scientific advancement will help pave the way for more people to live full, happy, and productive lives.

Thank you for your ongoing support and enjoy the evening!

Sincerely,

A handwritten signature in black ink, appearing to read "Jeffrey Borenstein". The signature is fluid and cursive, written in a professional style.

Jeffrey Borenstein, M.D.
President & CEO

- 4 Board of Directors & Dinner Committee
Sponsors & Contributors
- 6 **PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH**
Honoree:
Franca Ma-ih Sulem Yong
- Honorary Tribute:
Graham Boeckh Foundation
- 13 **LIEBER PRIZE**
FOR OUTSTANDING ACHIEVEMENT IN SCHIZOPHRENIA RESEARCH
Deanna M. Barch, Ph.D.
Washington University, St. Louis
- 14 **MALTZ PRIZE**
FOR INNOVATIVE & PROMISING SCHIZOPHRENIA RESEARCH
Nicole Karcher, Ph.D.
Washington University School of Medicine, St. Louis
- 15 **COLVIN PRIZE**
FOR OUTSTANDING ACHIEVEMENT IN MOOD DISORDERS RESEARCH
Nolan R. Williams, M.D.
Stanford University
- 16 **RUANE PRIZE**
FOR OUTSTANDING ACHIEVEMENT IN CHILD & ADOLESCENT PSYCHIATRIC RESEARCH
John N. Constantino, M.D.
Emory University
- Christopher J. McDougale, M.D.
Massachusetts General Hospital / Harvard Medical School
- 18 **GOLDMAN-RAKIC PRIZE**
FOR OUTSTANDING ACHIEVEMENT IN COGNITIVE NEUROSCIENCE RESEARCH
Cameron S. Carter M.D.
University of California Irvine School of Medicine
- 19 Previous Outstanding Achievement Prizewinners
- 30 BBRF Scientific Council

BOARD OF DIRECTORS

President & CEO

Jeffrey Borenstein, M.D.

President, Scientific Council

Judith M. Ford, Ph.D.

OFFICERS

Chairman

Geoffrey A. Simon

Vice President

John Osterhaus

Secretary

Judy Genshaft, Ph.D.

Treasurer

Miriam E. Katowitz

DIRECTORS

Carol A. Atkinson

J. Anthony Boeckh

Martin H. Borell

John Kennedy Harrison II

John B. Hollister

Carole H. Mallement

Milton Maltz

Jeffrey R. Peterson

Marc R. Rappaport

Mary Rubin

Virginia M. Silver

Ken Sonnenfeld, Ph.D., J.D.

Barbara K. Streicker

Barbara Toll

Robert Weisman, Esq.

DINNER COMMITTEE

Carol Atkinson

Raymonde and J. Anthony Boeckh

Janie and Martin Borell

Jeffrey Borenstein, M.D.

Judy Genshaft, Ph.D. and Steven Greenbaum

Marla Press and Ken Harrison

Kathy and John Hollister

Carole and Harvey Mallement

Tamar and Milton Maltz

Miriam Katowitz

Mary Pat and John Osterhaus

Jeffrey Peterson

Léa Darteville and Marc Rappaport

Mary Rubin

Virginia and Mark Silver, M.D.

Andrea and Geoffrey Simon

Kenneth Sonnenfeld, Ph.D., J.D. and

Peg Brivanlou, Ph.D., J.D.

Barbara Streicker

Barbara Toll

Frances and Robert Weisman, Esq.

SPONSORS

PLATINUM

Essel Foundation, Inc.

BRONZE

Alpine Saxon Woods, LLC
Columbia University Department of Psychiatry
Graham Boeckh Foundation
Maltz Family Foundation
Myrna Weissman, M.D.

SUPPORTERS

BENEFACTOR

Janie and Martin Borell
Peggy Burke
Léa Dartevelle and Marc Rappaport
Peg Brivanlou, Ph.D, J.D. and Kenneth Sonnenfeld, Ph.D., J.D.

AMBASSADOR

Anissa Abi-Dargham, M.D.
Victoria Arango, Ph.D
JSquared Press
Carol and Harvey Mallement
Mary Pat and John Osterhaus
Marylou Selo

VIP

Ballard Spahr
Andrew Boral
Wendy Cannon-Gunn
Judy Genshaft, Ph.D. and Steve Greenbaum
Caryl Goodman
Ann and Rob Laitman
Dolores Malaspina M.D., M.S., MSPH
Emily Merjan
PsychoGenics
Sheila Scharfman
Robert Simon
Amy Tisler and Jason Stipanov
Barbara Toll

INDIVIDUAL

Lillian Clagett
Miriam Katowitz
Lee Rodgers
Kenneth Simon
Barbara Wagner

HONOR ROLL

Margaret Ann Ricketts, Spot Solution

PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH



**DR. HERBERT
PARDES**

THIS INTERNATIONAL PRIZE RECOGNIZES

a physician, scientist, public citizen or organization whose extraordinary contribution has made a profound impact on advancing the understanding of mental health and providing hope and healing for people who are living with mental illness. Established in 2014 and awarded annually, the Pardes Humanitarian Prize is named in honor of Dr. Herbert Pardes, the first recipient of the award.

The recipient of the Prize is chosen by a distinguished international Selection Committee from nominations solicited worldwide and receives an honorarium. The Pardes Humanitarian Prize focuses public attention on the burden of mental illness on individuals and society and the urgent need to expand and enhance mental health services in the United States and globally.

No one has better described the goals of this international Prize than Dr. Pardes himself: "Mental illness is the largest single health challenge in the world. For many decades society has recognized major contributions in basic science, clinical research and clinical care in the non-psychiatric health fields. The Pardes Humanitarian Prize has been established to honor individuals who comprehensively care, teach, investigate, work, and passionately advocate for improving the mental health of society, and who have had a powerful impact on reducing the pain inflicted by psychiatric illness."

PARDES HUMANITARIAN PRIZE

SELECTION COMMITTEE

Celso Arango, M.D., Ph.D.

Head of Child and Adolescent Psychiatry Service
Hospital General Universitario Gregoria Maranon, Madrid

William T. Carpenter, Jr., M.D.

Professor Emeritus, Psychiatry
University of Maryland School of Medicine

Judith M. Ford, Ph.D.

Co-Director, Brain Imaging and EEG Lab
Professor, Department of Psychiatry
University of California, San Francisco

Robert Freedman, M.D.

University of Colorado School of Medicine

Patrice A. Harris, M.D., MA, FAPA

CEO, eMed

Medical Editor-in-Chief, Everyday Health
Visiting Professor, *Columbia University*

Dilip V. Jeste, M.D.

Social Determinants of Health Network

Helen S. Mayberg, M.D.

Professor of Neurology, Neurosurgery, Psychiatry,
and Neuroscience

Director, Center of Advanced Circuit Therapeutics and
Professor of Neurotherapeutics
Mount Sinai Health System

Maria A. Oquendo, M.D., Ph.D.

Ruth Meltzer Professor and Chairman of Psychiatry,
Perelman School of Medicine, University of Pennsylvania

American College of Neuropsychopharmacology, President
American Foundation for Suicide Prevention, President

Vikram Patel, Ph.D., F.Med.Sci.

Professor of Global Health & Social Medicine,
Dept. of Global and Social Medicine,
Harvard Medical School

Honorary Prof. of International Mental Health,
London School of Hygiene & Tropical Medicine, UK

Co-Founder & Member of Managing Cmt., Sangath, Goa, India

Adjunct Prof. & Joint Director,

Centre for Chronic Conditions & Injuries Public Health Fdn. of India

Judith L. Rapoport, M.D.

Chief, Child Psychiatry Branch

National Institute of Mental Health (NIMH/NIH)

Norman Sartorius, M.D., Ph.D., F.R.C.Psych.

President Association for the Improvement of
Mental Health Programmes

Carol A. Tamminga, M.D.

Professor and Chair of Psychiatry

Lou and Ellen McGinley Distinguished Chair in
Psychiatric Research

McKenzie Chair in Psychiatry

Chief of Translational Neuroscience Research in Schizophrenia

University of Texas (UT) Southwestern Medical School

Myrna M. Weissman, Ph.D.

Diane Goldman Kemper Family Professor of Epidemiology
(in Psychiatry)

Vagelos College of Physicians and

Surgeons, Columbia University



Rendering of The Pardes Humanitarian Prize medal
featuring Hygieia, Goddess of Health.

PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH



AWARDED TO
**FRANCA MA-IH
SULEM YONG**

FRANCA MA-IH SULEM YONG is a Cameroonian Creative Art Therapist/ Psychologist who has become known for her advocacy to promote tolerance, forgiveness, mental health and human fraternity as keys to sustainable peace.

Early in her career, she was a journalist who strived to change the way mental illness is viewed and represented in society. In 2015, she became the motive force behind Positive Youths Africa (PYA), a non-profit magazine and community outreach organization aimed at inspiring, engaging, and empowering youths to live a positive and purposeful life physically, mentally, and digitally.

A transformative turn in her career came in 2018 when she founded the Afrogiveness Movement. Fueled by personal loss and war trauma from Cameroon's Anglophone Conflict, she coined Afrogiveness from two words : "Africa " and "forgiveness." This movement has used the universal language and cathartic power of arts to heal survivors of conflict and intolerance (some of whom have been tortured, orphaned, and raped) while promoting tolerance and

peaceful co-existence. It has become a leading force for healing in Africa, offering psychosocial, educational, legal and socio-economic support to mentally traumatized survivors of conflict and intolerance.

In nominating Franca Ma-ih Sulem Yong for the Pardes Prize, Professor Nadine Machikou Ndzesop of the University of Yaounde 2, Cameroon, offered this testimonial: "Franca was the brain behind the Afrogiveness Movement which was using arts to heal mentally traumatized victims of conflict while empowering them to advocate for their rights. I visited her Afrogiveness Centre and was happy to see youths whose lives had been disrupted by armed conflict happy. I was further impressed to realize that she had self-funded most of her initiatives. Franca is one of those youths who is truly committed to mental health and peace building and I cannot even imagine how much further she will go if presented a prize like the Pardes Humanitarian Prize in Mental Health. It will empower her with the visibility, credibility and resources she needs to drive scalable impact."

HONORARY PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH



AWARDED TO
**THE GRAHAM
BOECKH
FOUNDATION**



THE GRAHAM BOECKH FOUNDATION (GBF) is a private foundation created in 1990 by J. Anthony Boeckh, his wife Raymonde, and his family. It was created to honor son Graham who had developed schizophrenia at age 18 and died from complications from antipsychotic medications.

In the past 14 years, the Foundation's primary interest has been mental health system change. It has done this primarily by focusing on the development of Integrated Youth Services (IYS) hubs across all the Canadian provinces and territories, including in cities, rural and remote areas, and Indigenous communities. GBF has led this system change through a number of public/private partnerships, collaborating with governments at all levels, communities, and a variety of corporations and family foundations.

IYS provides a holistic suite of services that are easily accessible to youths aged 12-25. The collection of data from IYS hubs is a key component in the Foundation's drive to create a learning health care system that will greatly improve the delivery of services to patients and families suffering from psychiatric illnesses. The IYS movement has been scaling up rapidly and is available or under development in approximately 150 communities in Canada.

The Graham Boeckh Foundation had previously led an international organization of over 30 major mental health research funders and partner organizations to share knowledge on research and other common interests.

PREVIOUS PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH WINNERS

2023 WINNER

Special Olympics International

Special Olympics International has had a profound and lasting humanitarian impact worldwide through its dedication to providing year-round sports training and athletic competition for children and adults with intellectual disabilities.

HONORARY TRIBUTE

Henry Jarecki, M.D.

Dr. Jarecki has had a profound humanitarian impact through his unique and lasting contribution to preserving academic and scientific freedom, including his role as the founding Chairman of the Scholar Rescue Fund of the Institute of International Education.

2022 WINNERS

Altha J. Stewart, M.D.

Dr. Stewart has devoted her career to helping the most disadvantaged and underserved people in our society who are living with serious mental illnesses. She is a pioneering voice in America about structural racism and its impact on mental health treatment for people of color.

Robert Van Voren, FRCPSYCH

Dr. Van Voren has dedicated his life to the cause of human rights and mental health, most recently in Ukraine and neighboring countries where he has organized services for people impacted by the war and provided essential medicines and supplies to institutions housing people with mental disorders.

HONORARY TRIBUTES

Clubhouse International

For more than 25 years Clubhouse International has pioneered the recovery concept for people living with mental illness, putting into practice their active participation in their own recovery process, a model that has been endorsed by governments, civil society, and professionals globally.

Sean Mayberry

StrongMinds, founded and led by Sean Mayberry, provide depression treatment to women in Africa, most with no access to effective treatment. Since its founding, StrongMinds has treated depression in 150,000 women and adolescents in Uganda and Zambia. On average, over 80% are depression-free following therapy.

2021 WINNERS

Kay Redfield Jamison, Ph.D.

Dr. Kay Jamison, a clinical psychologist, writer, and professor at Johns Hopkins University, serves as an inspiration to countless people living with bipolar disorder, and has helped transform how society sees those living with mental illness. Dr. Jamison has made a profound contribution to mental health awareness through her autobiography, "An Unquiet Mind," detailing her own struggles.

Elyn R. Saks, J.D., Ph.D.

Dr. Elyn Saks's pioneering contributions to our understanding of mental illness are seen through her work as a legal advo-

cate for the mentally ill, a volunteer at a psychiatric hospital, a therapist, an educator, and as an author. Her best-selling book, "The Center Cannot Hold: My Journey Through Madness," in which she provides a first-person account of her transition into psychosis and a lifetime spent as a person living with schizophrenia, has helped to transform our thinking about mental illness.

Charlene Sunkel

Charlene Sunkel is the Founder and CEO of the Global Mental Health Peer Network, the first group of its kind in the world that promotes and supports the empowerment of people who live with mental health problems. Ms. Sunkel herself has the experience of living with schizophrenia and is a great leader not only in her country of South Africa, but also around the world.

HONORARY TRIBUTES

John M. Davis, M.D.

Dr. John Davis is a tireless advocate and humanitarian in the mental health field, including his support for programming and services that provide better treatment for people with mental illness internationally. A mental health lobbyist, a defender of forensic psychiatry, and a devoted champion of young scientific investigators, he is the author of the first science-based textbook on psychopharmacology as a guide for psychiatrists seeking to use medications more effectively.

Michael R. Phillips, M.D.

Dr. Michael Phillips has dedicated his professional and personal life to serving as a mental health advocate in China. Having lived most of his career there, Dr. Phillips has not only brought mental health issues in China to the attention of the world, he has provided leadership on culturally sensitive interventions to address the problems he uncovers.

Norman Sartorius, M.D., Ph.D., FRCPsych

Dr. Norman Sartorius has helped to shape the field of mental health and psychiatry over the past 50 years through his humanitarian efforts, research, and work to advance the understanding of mental health. He has provided hope and healing worldwide for people who are living with mental illness, particularly those who live in low-income countries. Dr. Sartorius served as the first director of the World Health Organization's Department of Mental Health.

2020 WINNERS

Sir Michael Rutter, CBE

Professor Sir Michael Rutter was trained in general medicine, neurology and pediatrics before specializing in psychiatry. He is recognized as contributing to the establishment of child psychiatry as a medical and biopsychosocial specialty with a strong scientific base. In 1994, he established the Social, Genetic and Developmental Psychiatry Unit at the Institute of Psychiatry.

Myrna Weissman, Ph.D.

Dr. Myrna Weissman's research career, mostly as an epidemiologist, has focused on studying depression in families, seeking ways to break the cycle of transmission across generations and to develop better understanding of the mechanisms underlying transmission. Her current research

is on understanding the long-term risks of mood and anxiety disorders in individuals and transmitted to families, using methods of epidemiology, genetics, and neuroimaging. She developed Interpersonal Psychotherapy (IPT) with Gerald Klerman, M.D., and has since simplified and implemented it for health workers around the world.

doctors and nurses are often seen treating physical ailments: bandaging the war-wounded, rehydrating a cholera patient, or performing an emergency cesarean section. But for more than 20 years, MSF has also been providing vital psychiatric and psychological care to people ravaged by man-made or natural disaster. The organization currently has mental health-related programs in 41 countries across five continents treating adults and children.

HONORARY TRIBUTE

E. Fuller Torrey, M.D.

Dr. E. Fuller Torrey has made extraordinary contributions to people with mental illness, both in his research, which has had a profound impact on advancing the understanding of mental illness, and also by his advocacy for the rights of people with mental illness. In the 1970s Dr. Torrey introduced what was then a radically new and revolutionary approach, an infective/inflammatory etiology and pathophysiology of mental illness.

2019 WINNERS

William T. Carpenter, Jr., M.D.

Dr. William Carpenter has been a transformative force in psychiatry for over 40 years, dramatically changing how we treat schizophrenia, reducing stigma, and enhancing the ethics of treatment and research. He is a luminary in the field whose vision, scientific productivity and tireless advocacy for resources for psychiatric research have improved the lives of countless individuals and families.

HONORARY TRIBUTE

Cynthia Germanotta & Born This Way Foundation

Cynthia Germanotta and Born This Way Foundation are an extraordinary force for supporting and empowering young people by putting their needs, ideas and voices first. To help solve the issues facing today's youth, Cynthia Germanotta and Born This Way Foundation work to encourage and build communities that understand and prioritize mental and emotional wellness. They inspire us to look toward a future that supports the wellness of young people with an approach that is fiercely kind, compassionate, accepting, and inclusive.

2018 WINNER

Judge Steven Leifman

Judge Steven Leifman is a national leader in solving the complex and costly problem of people with untreated mental illnesses involved in the criminal justice system. He has been a passionate leader and unwavering agent of change in the shift away from the devastating and unproductive incarceration of people with mental illness. He has shown us how to use our resources to reverse the costly prison recidivism that strips people of their dignity and threatens public safety. Judge Leifman is an extraordinary humanitarian, innovator, and transformative figure whose steadfast advocacy is changing the lives of people with mental illness and their families, and impacting our larger society.

HONORARY TRIBUTE

Suzanne and Bob Wright

Suzanne and Bob Wright have been world leaders in autism advocacy. Their brave and tenacious leadership has created a rallying cry for concrete and larger-scale research, care, education, treatment and national and global awareness. Thanks to the extraordinary vision of Bob and Suzanne Wright, scientists have been able to develop a better understanding of the structures of autism, which are leading to helpful interventions. There are evolving trends in research that point to the interconnectivity between autism and other medical conditions.

2017 WINNER

Doctors Without Borders/Médecins Sans Frontières

Doctors Without Borders/Médecins Sans Frontières (MSF) provides emergency medical aid in response to armed conflicts, natural disasters, famines, and epidemics. MSF

HONORARY TRIBUTE

Constance E. Lieber

Constance E. Lieber transformed her family's experience with mental illness into a lifetime of extraordinary advocacy and support for psychiatric research of schizophrenia, depression, and other mental illnesses. She was unwavering in her dedication to alleviating the suffering caused by mental illness and banishing the stigma that for too long has been associated with psychiatric disorders.

2016 WINNERS

Vikram Patel, Ph.D., F.Med.Sci.

Recognized by Time magazine in 2015 as one of the 100 Most Influential People in the world, Dr. Patel addresses the stunning void of mental health care in developing countries and the grave shortage of psychologists and psychiatrists. He was awarded for his transformative work in advancing mental health care in resource-poor countries.

Charles F. Reynolds, III, M.D.

Dr. Reynolds and his colleagues have made groundbreaking contributions to the prevention and treatment of depression in older adults. He was awarded for his pioneering work in geriatric psychiatry and the prevention and treatment of late-life depression.

HONORARY TRIBUTE

Senator Edward M. Kennedy

He was honored, posthumously, for his powerful and unwavering commitment to advocating on behalf of people with mental illness. The award was accepted by his son Patrick J. Kennedy, Former Congressman (D-RI).

2015 WINNERS

Beatrix (Betty) A. Hamburg, M.D. and David A. Hamburg, M.D.

Dr. Betty Hamburg and Dr. David Hamburg blended their scientific knowledge, their understanding of human behavior, and their profound compassion into a unique vision—imagining and catalyzing a better future for people of all ages and backgrounds, most often those who are undergoing severe stress and who suffer from mental disorders. Betty and David Hamburg were awarded for over six decades of pioneering work in mental health.

HONORARY TRIBUTE

Rosalynn Carter

Former First Lady, Rosalynn Carter was honored for her tireless work in mental health advocacy.

2014 WINNER

Herbert Pardes, M.D.

Dr. Pardes, a noted psychiatrist, and outspoken advocate for the mentally ill, was the first recipient of the Humanitarian Prize, which bears his name and honors individuals who have made significant contributions to the field of mental health through education, prevention, treatment, research, health policy, administration, clinical care, mentoring and advocacy. Dr. Pardes is a champion of empathic, humanistic and patient-centered health care, who believes in the power of technology and innovation to dramatically improve 21st-century medicine.

OUTSTANDING ACHIEVEMENT PRIZES

Tonight we celebrate the transformative power of neuroscience and psychiatric research to improve the lives of those living with mental illness. Five exceptional scientists, selected by the Brain & Behavior Research Foundation's Scientific Council, will be honored for their outstanding lifetime achievements in brain and behavior science.

The Outstanding Achievement Prizes are awarded annually and include the:

Lieber Prize for Schizophrenia Research

Established in 1987 by Constance and Stephen Lieber to bring public recognition to the outstanding discoveries being made in schizophrenia research. This prize carries an award of \$50,000.

Maltz Prize for Innovative & Promising Schizophrenia Research

Established in 2004, the prize was formerly known as the Baer Prize and was renamed in 2016 in honor of Board Members Milton and Tamar Maltz. The Maltz Prize provides \$40,000 to an investigator who has undertaken innovative and promising research in schizophrenia. Winners of this prize are selected by the Lieber Prize recipient(s) of the same year.

Colvin Prize for Mood Disorders Research

Established in 1993, this prize was formerly known under the successive titles of the Selo Prize, Falcone Prize, and Bipolar Mood Disorders Prize. The prize was renamed in 2012 in honor of the late Oliver D. Colvin, Jr., a great benefactor of the Foundation who left the largest single contribution in the Foundation's history. This prize carries an award of \$50,000.

Ruane Prize for Childhood & Adolescent Psychiatric Research

This prize was initiated in 2000 by philanthropists Joy and William Ruane to recognize important advances in understanding and treatment of early-onset brain and behavior disorders. This prize carries an award of \$50,000.

Goldman-Rakic Prize for Cognitive Neuroscience

This prize was created by Constance and Stephen Lieber in memory of Patricia Goldman-Rakic, Ph.D., a distinguished neuroscientist renowned for discoveries about the brain's frontal lobe, after her tragic death in an automobile accident in 2003. The prize carries an award of \$40,000.

Scientific Council Prize Committees

LIEBER PRIZE

William E. Bunney, Jr., M.D. (Chair)
Robert Freedman, M.D.
Raquel Gur, M.D., Ph.D.
Kenneth S. Kendler, M.D.
David A. Lewis, M.D.
Carol Tamminga, M.D.
Daniel Weinberger, M.D.

COLVIN PRIZE

Robert M. Post, M.D. (Chair)
Wade Berrettini, M.D., Ph.D.
Hilary Blumberg, M.D.
William E. Bunney, Jr., M.D.
Andrew Nierenberg, M.D.
Karen Dineen Wagner, M.D., Ph.D.

RUANE PRIZE

Daniel Pine, M.D. (Chair)
Joseph T. Coyle, M.D.
James E. Leckman, M.D., Ph.D.
Joan Luby, M.D.
Matthew State, M.D.
Anita Thapar, M.B., B.Ch., M.R.S.Psych., Ph.D.
Jeremy Veenstra-VanderWee, M.D.

GOLDMAN-RAKIC PRIZE

Amy F.T. Arnsten, Ph.D. (Chair)
Robert Desimone, Ph.D.
Suzanne N. Haber, Ph.D.
Michael I. Posner, Ph.D.
David Silbersweig, M.D.

LIEBER PRIZE

FOR OUTSTANDING ACHIEVEMENT IN SCHIZOPHRENIA RESEARCH



Deanna M. Barch, Ph.D.

Professor of Psychological & Brain Sciences,
Psychiatry, and Radiology
Vice Dean of Research, Arts & Sciences
Gregory B. Couch Professor of Psychiatry

Washington University, St. Louis

- BBRF Scientific Council Member
- 2013 BBRF Distinguished Investigator
- 2006 BBRF Independent Investigator
- 2000, 1995 BBRF Young Investigator

"The Liebers were pioneers in the field of promoting research on serious mental illness and have been an inspiration to generations of researchers in the field. BBRF provided me with my very first funding support for my work on psychosis, and I am so grateful and honored to receive this award in the Liebers' name."

Dr. Barch's research focuses on understanding normative patterns of cognitive function and brain connectivity, and the mechanisms that give rise to the challenges in behavior and cognition found in illnesses such as schizophrenia and depression, utilizing psychological, neuroimaging, and computational approaches across the lifespan.

In particular, she is interested in determining the cognitive, emotional and neural bases of risk for the development of schizophrenia and depression, potentially as a means of developing better

preventative approaches. She uses functional MRI, structural MRI, and cognitive neuroscience methods to examine the neural basis of disturbances in cognitive control and emotional processing in individuals with schizophrenia and those at risk for the development of schizophrenia, as well as in individuals with mood disorders. Further, her work includes a focus on the ways in which early adversity (e.g., poverty, stress, and disparities in access to health care) shape early brain development and subsequent risk for mental health challenges.

"Dr. Barch is a remarkable schizophrenia researcher who has made continuous critical contributions over her career. She is a leader in the study of cognitive and affective neuroscience in schizophrenia. Her earliest work defined and described context processing, now widely seen to be a central neuroscience construct. She has defined the study of neural representations of goals and emotional drive which are the critical underpinnings of reduced emotional experience in schizophrenia. Her work on effort allocation and effort-based decision making has enhanced our understanding of failures in sustained reinforced effort, which could be a major driver of disability in schizophrenia. She continues to make major contributions to multiple genomic, imaging, and assessment initiatives."

—Dr. William Bunney, Chair, Lieber Prize Committee

MALTZ PRIZE

FOR INNOVATIVE & PROMISING SCHIZOPHRENIA RESEARCH



Nicole Karcher, Ph.D.

Assistant Professor of Psychiatry

Washington University School of Medicine,
St. Louis

"It is an incredible honor to receive the Maltz prize, following in the footsteps of so many amazing researchers. I am very grateful to the BBRF for this acknowledgment of my research pushing the boundaries of knowledge about early risk factors for psychosis spectrum symptoms."

Dr. Karcher's research focuses on understanding the neural, genetic, cognitive, and environmental factors underlying the development and persistence of psychotic-like experiences in childhood and adolescence.

She uses several methodologies, including functional MRI, structural MRI, epidemiological, and genomic approaches to the study of the etiology of psychotic-like experiences. She is also motivated to develop identification and prevention efforts for children and adolescents at risk for the development of psychotic experiences, including efforts to reduce mental health disparities.

"Dr. Karcher's work importantly advances our knowledge about the origins, mechanisms, and outcomes of psychopathology, with an emphasis on understanding the pathogenesis of psychosis spectrum symptoms. She has helped transform our understanding of early childhood and adolescent psychotic-like experiences. This work has fundamentally improved our understanding of the role of genetics, pathophysiology, and environment in the development and worsening of early psychosis spectrum symptoms. She has made critical strides in understanding mechanisms underlying risk for psychopathology, leveraging large-scale datasets to understand the role of structural neural metrics and environmental insults such as experiences of discrimination in the development of psychosis spectrum symptoms."

—Dr. Deanna Barch, winner of the 2024 BBRF Lieber Prize

COLVIN PRIZE

FOR OUTSTANDING ACHIEVEMENT IN MOOD DISORDERS RESEARCH



Nolan R. Williams, M.D.

Associate Professor of Psychiatry and Behavioral Sciences
Director, Stanford Interventional Psychiatry Clinical Research
Director, Stanford Brain Stimulation Laboratory

Stanford University

- 2019 BBRF Klerman Prize for Exceptional Clinical Research
- 2018, 2016 BBRF Young Investigator

"I am deeply humbled and honored to receive the Colvin Prize. Many of my mentors have received this esteemed award, and I stand on their shoulders as I accept this recognition. The BBRF was the first to believe in several of the ideas that have become central to our lab and our research. Their early, unwavering support enabled us to pursue innovative and alternative therapeutics. I am sincerely grateful for their continued support of bold, early-stage neuropsychiatric research."

Dr. Williams focuses on developing innovative technologies and therapeutics to modulate neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team employs neuroimaging-based approaches to target therapeutic delivery and predict treatment responses. Dr. Williams, who earned his M.D. and completed dual residencies in neurology and psychiatry at the Medical University of South Carolina, is triple board-certified in general neurology, general psychiatry, and behavioral neurology & neuropsychiatry. Over the past decade, his lab has pioneered several novel therapeutic

approaches, including Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant depression, which received FDA Breakthrough Device Designation and Clearance and is covered by Medicare NTAP/New Tech APC. SAINT is deployed in clinical and research settings worldwide. Dr. Williams also conducts mechanistic clinical trials on rapid-acting experimental pharmacological agents such as ibogaine and ketamine.

"Dr. Williams has played a crucial role in developing a new form of accelerated transcranial magnetic stimulation, called the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). In clinical tests, high rates of response were seen in 5 days in patients with treatment-refractory unipolar and bipolar depression. Work is ongoing with other patients, such as those with PTSD. Dr. Williams' work holds the promise of revolutionizing the treatment of refractory depression and other illnesses, and thus of making a dramatic improvement in the treatment of these disabling illnesses and the lives of countless patients."

—Robert M. Post, M.D., Chair, Colvin Prize Committee

RUANE PRIZE

FOR OUTSTANDING ACHIEVEMENT IN CHILD & ADOLESCENT PSYCHIATRIC RESEARCH



John N. Constantino, M.D.

Chair and Chief, Center for Behavioral and Mental Health, Children's Healthcare of Atlanta
Professor of Psychiatry & Behavioral Sciences, Pediatrics, and Genetics

Emory University

"I am thrilled to be counted among those recognized by BBRF for contributions to research in child and adolescent psychiatry and am profoundly grateful to the Foundation for all it has done during my lifetime to advance our field."

John N. Constantino is a child psychiatrist and pediatrician whose research focuses on understanding genetic and environmental influences on disorders of social development in childhood, for the purpose of preventing or ameliorating lifelong impairment. He and his team developed and systematically validated the Social Responsiveness Scale, a quantitative scale for rating the characterizing traits and symptoms of autism that has been translated into over 60 foreign languages and is used worldwide as a measurement standard in research and clinical settings. His work has revolutionized understanding autism as a condition that lies at the extreme of a continuous distribution of variation in social behavior that

extends throughout the general population. This has led to a clearer understanding of mechanisms of inheritance in autism, and the identification of a discrete set of developmental liabilities that constitute new, tractable targets for higher-impact early intervention, including early social visual engagement. In parallel, he and his team have worked to understand and offset the influence of early adverse environmental experience on social development in childhood, particularly in relation to child maltreatment, which affects 1 in 8 U.S. children. It is a direct cause of enduring psychiatric disorders over the life course and is often preventable.

"Dr. Constantino has identified the range of presentations that occur in autism spectrum disorders, highlighting the connections with many other forms of psychopathology and with healthy functioning. He has linked these varied presentations and their correlates in measures of brain function to pathophysiologic factors through research utilizing techniques from genetic epidemiology."

—Daniel S. Pine, M.D., Chair, Ruane Prize Committee

RUANE PRIZE

FOR OUTSTANDING ACHIEVEMENT IN CHILD & ADOLESCENT PSYCHIATRIC RESEARCH



Christopher J. McDougle, M.D.

Director, Lurie Center for Autism
Professor of Psychiatry

Massachusetts General Hospital /
Harvard Medical School

- 1997 BBRF Independent Investigator
- 1994, 1990 BBRF Young Investigator

"I am humbled and grateful to receive the 2024 Ruane Prize. I am fortunate to have been mentored by many outstanding individuals and leaders in our field throughout my training and professional career. It is a great honor to be among the previous winners of this award."

Christopher J. McDougle, M.D. is an internationally renowned expert in the neuropsychopharmacology of childhood-onset neurodevelopmental disorders and has dedicated his career to studying these disorders across the lifespan.

He has 25 years of experience diagnosing and caring for children, adolescents, and adults with autism spectrum disorders (ASDs). Before coming to Mass General, Dr. McDougle was the chairman of the department of psychiatry and executive director of the Institute of Psychiatric Research at Indiana University School of Medicine, where he was also the Albert Eugene Sterne Professor of Psychiatry. Dr. McDougle has maintained an active clinical

practice throughout his career and continues this commitment to caring for individuals with ASDs at the Lurie Center, where he has expanded services for adults. As director of the Lurie Center, Dr. McDougle is keenly interested in leveraging the vast resources that exist at Mass General and elsewhere in Boston to advance new discoveries and treatments for children, adolescents, and adults with ASDs.

"Dr. McDougle's research on treatment and its relation to both biological and other neurodevelopmental factors has had a particularly profound impact. He has conducted important clinical trials on a range of mental conditions, including obsessive compulsive disorder and a range of neurodevelopmental syndromes. In particular, his studies on the safety and efficacy of medications for the treatment of autism spectrum disorder actively shape current practice."

—Daniel S. Pine, M.D., Chair, Ruane Prize Committee

GOLDMAN-RAKIC PRIZE

FOR OUTSTANDING ACHIEVEMENT IN COGNITIVE NEUROSCIENCE RESEARCH



Cameron S. Carter M.D.

Professor & Chair, Department of Psychiatry and Human Behavior

University of California Irvine School of Medicine

- BBRF Scientific Council Member
- 2007 BBRF Distinguished Investigator
- 2001 BBRF Klerman Prize for Exceptional Clinical Research
- 1997, 1994 BBRF Young Investigator

"Having known Patricia Goldman Rakic very early in my career, been influenced and inspired by her seminal studies in animal model systems and in clinical populations, and encouraged by the enthusiasm she expressed at the time for my work, receiving this Prize in her name is very deeply meaningful. I feel so honored and moved to be recognized with this prize in her memory."

Dr. Carter is a psychiatrist and cognitive neuroscientist who has made seminal contributions to the field of cognitive neuroscience, conducting some of the first event-related fMRI studies. This work resulted in many high impact papers and introduced a novel network model of the frontal cortex supporting a general-purpose cognitive control function that remains influential to this day.

Dr. Carter was also one of the first to apply these methods to understand the circuitry disruptions that underlie cognitive deficits and other symptoms of schizophrenia, bipolar disorder, depression, OCD and autism. His approach was strongly influenced by the groundbreaking work of Patricia Goldman-Rakic in focusing on the dorsolateral prefrontal cortex as a key hub in brain systems that are affected by schizophrenia. These studies have resulted in new

insights into the structure of psychopathology, helped guide targeted treatment development, and contributed to early progress in developing imaging biomarkers for schizophrenia.

Throughout his career Dr. Carter has bridged basic cognitive and clinical neuroscience. He has promoted his vision and led by example, conducting impactful experimental studies in healthy and patient populations, and by assembling and leading collaborative teams of basic and clinical neuroscientists to address the challenges of understanding psychosis. His leadership in this area has influenced the development of the NIMH Research Domain Criteria and other paradigm shifts in mental health research.

"Dr. Carter's research has pioneered the use of human brain imaging to illuminate the role of the prefrontal and anterior cingulate cortices in cognitive control, and the dysfunction of these circuits in schizophrenia, research that is closely related to Pat Goldman-Rakic's landmark discoveries on the role of prefrontal cortex in top-down control. His group also examines the effects of maternal immune inflammation on prefrontal cortical neuronal structure and dopamine actions, helping to explain why perinatal inflammation is a risk factor for schizophrenia."

—Dr. Amy Arnsten, Chair, Goldman-Rakic Prize Committee

PREVIOUS OUTSTANDING ACHIEVEMENT PRIZEWINNERS

Listing reflects prizewinners' affiliation when they received the prize

LIEBER PRIZE

1987 Benjamin S. Bunney, M.D.

Yale University

Influential studies of neuronal systems that use dopamine as their chemical messenger, implicated in the pathogenesis of schizophrenia and other disorders, and targeted by key medicines.

1988 Philip Holzman, Ph.D.

Harvard University

Pioneering discoveries about cognitive dysfunction in schizophrenia, as well as dysfunction in eye-tracking.

1989 Timothy Crow, M.D.

Oxford University, UK

Historic CT studies showed structural changes in the brains of schizophrenia patients; made influential distinctions between "positive" and "negative" symptoms.

1990 Philip Seeman, M.D., Ph.D.

University of Toronto, Canada

Discovered the dopamine receptor targeted by antipsychotic medicines, now called the dopamine D2 receptor.

1991 Patricia Goldman-Rakic, Ph.D.

Yale University

Discovered and described the circuitry of the prefrontal cortex and its relationship to working memory; transformed research on the neurobiological basis of higher cognitive function.

1992 John M. Kane, M.D.

Albert Einstein College of Medicine

Pioneer in the study of first-episode schizophrenia; conducted groundbreaking work with clozapine for treatment-resistant schizophrenia.

Herbert Y. Meltzer, M.D.

Vanderbilt University

Principal investigator of seminal trials leading to approval of clozapine for treatment-resistant schizophrenia and patients who are at high risk for suicide.

1993 Daniel R. Weinberger, M.D.

National Institute of Mental Health

Instrumental in focusing research on the role of abnormal brain development as a risk factor, and in some cases, a causal factor in schizophrenia.

1994 Arvid Emil Carlsson, M.D.*

University of Gothenburg, Sweden

Nobel laureate. Developed a method for measuring the amount of dopamine in brain tissues, relevant to dopamine hypothesis in schizophrenia and leading separately to medicines for Parkinson's disease.

1995 Kenneth S. Kendler, M.D.

Virginia Commonwealth University

Pioneer in psychiatric genetics, in disorders including schizophrenia, major depression, alcoholism, personality disorders, and nicotine dependence.

1996 Paul Greengard, Ph.D.*

The Rockefeller University

Nobel laureate. Made historic discoveries about the workings of neurotransmitter systems in the brain.

1997 Lars Farde, M.D., Ph.D.

Karolinska Institutet, Sweden

Authority on D1-dopamine receptor availability in first-episode psychosis.

Göran C. Sedvall, M.D., Ph.D.

Karolinska Institutet, Sweden

Authority on pharmacological manipulation of D1-dopamine receptor function in schizophrenia.

1998 George K. Aghajanian, M.D.

Yale University

Discoveries on mechanisms of chemical neurotransmission in the central nervous system.

Sarnoff A. Mednick, Ph.D., Dr. Med.

University of Southern California

A pioneer of the prospective high-risk longitudinal study to investigate the causes of disorders, most notably, schizophrenia.

1999 Salomon Z. Langer, Ph.D.

Compugen, Israel

Pioneer in receptor biology and discoverer of various drugs for treatment of psychiatric disorders.

Richard Jed Wyatt, M.D.

National Institute of Mental Health

Chief of NIMH neuropsychiatry branch who made early advances in the study and treatment of schizophrenia.

2000 Nancy C. Andreasen, M.D., Ph.D.

University of Iowa

Recognized that negative symptoms and associated cognitive impairments in schizophrenia had more debilitating effects in terms of functional recovery than psychotic symptoms; pioneer in neuroimaging.

William T. Carpenter, Jr., M.D.

University of Maryland

Influential approach to the care and study of schizophrenia patients encompassed a medical model integrating biological, psychological, and social data pertinent to diagnosis, treatment, and etiology.

*Recipient of the 2000 Nobel Prize in Physiology or Medicine.

LIEBER PRIZE

2001 Solomon H. Snyder, M.D.

The Johns Hopkins University

Fundamental discoveries in receptor biology permitted characterization of receptors in biochemical detail, leading to major advances in drug discovery.

2002 Francine M. Benes, M.D., Ph.D.

Harvard University

Demonstrated that connections of the basolateral amygdala with the anterior cingulate cortex and hippocampus likely play pivotal role in schizophrenia and bipolar disorder.

2003 Robin Murray, M.D., DSc.

King's College London, Institute of Psychiatry, UK

An innovator in psychosis research; first to link heavy cannabis use with psychosis onset.

2004 Joseph T. Coyle, M.D.

Harvard University

Pathbreaking studies of glutamate and its role in the origins, development, and pharmacological treatment of schizophrenia.

2005 David A. Lewis, M.D.

University of Pittsburgh

Pathbreaking efforts to define neural processes that give rise to cognitive deficits of schizophrenia.

2006 Jeffrey A. Lieberman, M.D.

Columbia University

Studies of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic medicines.

2007 Eve C. Johnstone, M.D.

University of Edinburgh, Scotland

Historic imaging studies showed differences in brains of people with schizophrenia; leader of the influential Edinburgh High Risk Study, involving young people with family history of the illness.

2008 Irving I. Gottesman, Ph.D.

University of Minnesota

Historic studies of identical twins documented the contributions of genetics and family, social, cultural, and economic factors to the onset, progress, and transmission of schizophrenia.

2009 Raquel E. Gur, M.D., Ph.D.

University of Pennsylvania

Examined neurocognitive functions as markers in multiplex families with schizophrenia; probed brain circuitry underlying core negative symptoms of schizophrenia; studies of individuals with comorbid mental illness/AIDS.

Ruben C. Gur, Ph.D.

University of Pennsylvania

Computer-based tools for “deep phenotyping” of brain and behavioral features integrating clinical and neurocognitive measures with neuroimaging and genomic data; documented abnormal regional brain functions associated with multiple illnesses.

2010 Ming T. Tsuang, M.D., Ph.D., DSc.

University of California, San Diego

Pioneer in the development of diagnostic and predictive biomarkers for psychiatric illnesses including schizophrenia.

2011 Joel E. Kleinman, M.D., Ph.D.

National Institute of Mental Health

Helped build an important collection of postmortem human brains for the study of the molecular biology of brain development and related disorders, especially schizophrenia.

Carol A. Tamminga, M.D.

University of Texas Southwestern Medical Center at Dallas

Evaluated the function of the living brain in individuals with and without schizophrenia using brain imaging; used human postmortem brain tissue to discover functional alterations.

2012 Michael O'Donovan, M.D., Ph.D.

Cardiff University, Wales

Applied molecular genetic technology to identify specific risk genes for schizophrenia and optimize treatment decisions for individual patients.

Michael J. Owen, M.D., Ph.D.

Cardiff University, Wales

Applied molecular genetic technology to identify specific risk genes for schizophrenia and optimize treatment decisions for individual patients.

2013 Marc G. Caron, Ph.D.

Duke University Medical Center

Generated the first dopamine transporter “knockout” mouse; groundbreaking study identified a novel mode of signaling for the brain's dopamine D2 receptors.

2014 David L. Braff, M.D.

University of California, San Diego School of Medicine

Research to identify the genetic basis of neurophysiologic and cognitive abnormalities of schizophrenia.

Patrick F. Sullivan, M.D., FRANZCP

Karolinska Institute,

University of North Carolina at Chapel Hill

Co-leader of Psychiatric Genomics Consortium (PGC), conducting mega-analyses of genetic variation across psychiatric disorders; obtained first reproducible GWAS results for schizophrenia.

2015 Robert Freedman, M.D.

University of Colorado, Denver

Developed a simple and safe preventive strategy—maternal choline supplementation during pregnancy—to bolster inhibition in the fetal brain, and thereby lessen schizophrenia risk.

Patrick McGorry, M.D., Ph.D FRCP, FRANZCP

Orygen and University of Melbourne

Strong advocate for shifting the therapeutic paradigm for schizophrenia to early detection and intervention in young people; led development of evidence-based therapies with controlled trials.

LIEBER PRIZE

2016 Michael F. Green, Ph.D.

University of California, Los Angeles

A leading researcher in the evaluation of social cognitive retraining and novel pharmacological interventions to improve cognitive impairments.

Stephen R. Marder, M.D.

University of California, Los Angeles

With Michael Green, led the NIMH-MATRICES initiative, which addressed key issues in the development of medications for improving cognition in schizophrenia.

2017 John M. Davis, M.D.

University of Illinois at Chicago

Conducted the first studies of how antipsychotic drugs are metabolized and how this process may impact their efficacy and side effects.

2018 Anissa Abi-Dargham, M.D.

Stony Brook University

Pioneering molecular imaging studies showed increased striatal dopamine release in schizophrenia, a candidate biomarker for risk to develop schizophrenia in prodromal patients.

Schahram Akbarian, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Studies of genome organization and function in brain cells have led to major insights about epigenetic mechanisms implicated in schizophrenia and other psychiatric illnesses.

2019 Alan S. Brown, M.D., M.P.H.

Columbia University

Has revealed prenatal factors that increase risk for schizophrenia. Made the breakthrough finding that inflammation caused by the mother's response to infection could play a causative role.

John J. McGrath M.D., Ph.D.

Queensland Centre for Mental Health Research

Epidemiological findings including on the incidence of schizophrenia, variations of the disorder between sites, and the increase of mortality in those with schizophrenia.

2020 Anne S. Bassett, M.D., F.R.C.P.C.

University of Toronto

Research establishing 22q11.2 deletion syndrome as the first molecular genetic subtype of schizophrenia.

2021 Ezra S. Susser, M.D., Dr.PH

Columbia University, New York State Psychiatric Institute

Research on the determinants of the onset and course of schizophrenia and childhood neurodevelopmental disorders, with a major focus on global mental health.

2022 Robert Schwarcz, Ph.D.

University of Maryland School of Medicine

Karolinska Institute, Stockholm

Research on the neurobiology of quinolinate and kynurenate, metabolically related brain constituents with neuroexcitatory and neuroinhibitory properties, and products of the kynurenine pathway.

2023 Philip D. Harvey, Ph.D.

University of Miami

VA Medical Center, Miami

Research focused on reducing the disability associated with schizophrenia by trying to advance the assessment and treatment of cognitive impairments, functional skills, and negative symptoms.

MALTZ PRIZE

FORMERLY KNOWN AS BAER PRIZE

2004 Jonathan Picker, M.D., Ph.D.

Harvard University

Research on maternal folate and homocysteine levels and their possible role in neurodevelopmental processes which may relate to schizophrenia genesis.

2005 Takanori Hashimoto, M.D., Ph.D.

University of Pittsburgh

Studies of cortical deficits in schizophrenia, focusing on neural oscillations, which reflect coordinated activities of local neuron assemblies.

2006 Lorna W. Role, Ph.D.

Columbia University

Focused on dissecting the role of cholinergic signaling in neural circuits and behaviors related to emotional salience in learning and memory; studies of neuregulin-1 risk gene and circuit dysfunction.

2007 Jeremy Hall, M.D., Ph.D.

Edinburgh University, Scotland

Studies of the interaction of genetic and environmental risk factors in the development of psychiatric disorders including schizophrenia, mood and personality disorders.

2008 Angus W. MacDonald, III, Ph.D.

University of Minnesota

Studies of what happens when cognitive and affective processes break down in psychiatric illness, with an emphasis on psychosis and schizophrenia.

2009 Daniel H. Wolf, M.D., Ph.D.

University of Pennsylvania

Utilizing pharmacological challenges during fMRI neuroimaging in schizophrenia plus detailed clinical and behavioral assessments to relate specific negative symptoms to specific circuit dysfunctions.

MALTZ PRIZE

2010 Stephen J. Glatt, Ph.D.

SUNY Upstate Medical University

Seeks to identify risk genes for psychiatric disorders by studying affected individuals and families, then studying how such genes may alter brain biology, leading to a vulnerability.

2011 Elena I. Ivleva, M.D.

University of Texas Southwestern Medical Center

Research that seeks to identify biological markers that underlie mechanisms of psychosis.

Amanda J. Law, Ph.D.

National Institute of Mental Health

Research that defined molecular and cellular mechanisms behind the genetic association of the NRG1, NRG3 and ErbB4 genes with psychosis and cognitive impairment in schizophrenia.

2012 James T. R. Walters, M.D., Ph.D.

Cardiff University, Wales

Identified a schizophrenia risk gene as being associated with episodic memory and with smaller volume in the hippocampus, a brain area involved in episodic memory deficits.

2013 Kafui Dzirasa, M.D., Ph.D.

Duke University

Studies how genetic mutations that confer risk for neuro-psychiatric illnesses alter circuits that underlie cognitive and affective symptoms in mouse models.

Nikhil M. Urs, Ph.D.

Duke University

Developing animal models as tools for understanding the brain mechanisms that give rise to schizophrenia and other brain disorders.

2014 Gregory Light, Ph.D.

University of California, San Diego/San Diego Veterans

Affairs Department

Performed EEG studies of the brain in schizophrenia that have given rise to new ways of treating cognitive deficits.

Stephan Ripke, M.D.

Psychiatric Genomics Consortium

Designing, implementing, and running the genomic analysis pipeline that is the cornerstone of the pioneering efforts of the Psychiatric Genomic Consortium (PCG).

2015 M. Camille Hoffman, M.D., MSCS

University of Colorado, Denver

Research to understand how positive and negative factors in human pregnancy influence maternal health, and critical periods of fetal and early childhood brain development; helped demonstrate that maternal choline supplementation can reduce child's mental illness risk.

Barnaby Nelson, Ph.D.

Orygen and University of Melbourne

Looks at prodromal phase of psychotic disorders, with interest in integrative models involving self and world experience in schizophrenia, cognitive biases, and the role of stress and trauma in disease onset.

2016 William P. Horan, Ph.D.

University of California, Los Angeles

Research on treatments that enable people with psychosis to live independently, pursue vocational and educational goals, and develop more satisfying social networks in the community.

Amanda McCleery, Ph.D.

University of California, Los Angeles

Research focusing on cognitive predictors of functional outcome in schizophrenia; using EEG techniques and performance-based measures to understand the trajectory of cognition over the course of illness.

2017 Deanna L. Kelly, PharmD., BCPP

University of Maryland School of Medicine

Treatment-oriented research looking at the biologic differences and side effects of women with schizophrenia; also studying inflammation, diet, and psychiatric symptoms.

2018 Kristen Brennand, Ph.D.

Icahn School of Medicine at Mount Sinai

Using stem-cell technology to reprogram patients' skin cells to redevelop as neurons to gain novel insights into the molecular and cellular phenotypes of mental illness.

Guillermo Horga, M.D., Ph.D.

New York State Psychiatric Institute / Columbia University

Describing relationships between dopamine abnormalities and downstream cortical dysfunctions associated with psychosis symptoms, aiming to formulate a computational model.

2019 Christoph Kellendonk, Ph.D.

Columbia University Irving Medical Center / New York State

Psychiatric Institute

Groundbreaking studies using mouse genetic tools and environmental risk factors to understand the biology that underlies the cognitive and negative symptoms of schizophrenia.

James P. Kesby, Ph.D.

Queensland Brain Institute

Examines how dysfunction in the associative striatum produces hallucinations and delusions (psychosis) and contributes to poor decision making in people with schizophrenia.

2020 Melissa Gymrek, Ph.D.

University of California, San Diego, Institute for Genomic

Medicine

Research on repetitive regions of the genome, a major source of genetic variation, including repetitive DNA variants known as short tandem repeats as a model for complex variation.

2021 Lawrence H. Yang, Ph.D.

School of Global Public Health, New York University

Research evaluating the preventive potential and risks associated with the "clinical high-risk" state for psychosis (CHR) designation, particularly as it concerns potential stigma; studies of untreated psychosis in China.

2022 Sophie Erhardt, Ph.D.

Karolinska Institute, Stockholm

Has provided fundamentally new insights into the mechanisms by which elevations in brain kynurenic acid impair the function of dopamine and glutamate.

2023 Amy E. Pinkham, Ph.D.

University of Texas at Dallas

Has identified factors that contribute to social difficulties in schizophrenia, focusing on social cognition, or how we think about other people.

COLVIN PRIZE

FORMERLY KNOWN AS SELO PRIZE

1993 Robert M. Post, M.D.

Pennsylvania State Hospital

Pioneered use of the anticonvulsant carbamazepine as treatment for lithium-resistant patients with bipolar disorder; early explorer of non-invasive brain stimulation for unipolar and bipolar depression.

1994 Jules Angst, M.D.

Psychiatric University Hospital, Zurich, Switzerland

Leader in research on bipolar disorder; helped more clearly define various subtypes; studied life-long recurrence risk of bipolar I, bipolar II and major depressive disorders; identified risk factors.

Myrna M. Weissman, Ph.D.

New York State Psychiatric Institute / Columbia University

Research focused on understanding the rates and risks of mood and anxiety disorders; pathbreaking multi-generational study of women identified their elevated depression risk and the impact of maternal depression—and treatment—on offspring.

1995 Claude de Montigny, M.D., Ph.D.

McGill University, Canada

A translational pioneer who developed lithium augmentation therapy for treatment-resistant depression; researched impact of benzodiazepines on hippocampal neurons.

1996 Wade Berrettini, M.D., Ph.D.

University of Pennsylvania

Research on the genetics and pharmacogenetics of several complex traits, including addictions, mood disorders, eating disorders, and epilepsy.

Elliot S. Gershon, M.D.

University of Chicago

Pioneer in genetic epidemiology, creating new methods for family studies of disease. Authority on genetic and chromosomal disorders and re-arrangements that predispose to psychiatric disorders.

J. Raymond DePaulo, Jr., M.D.

The Johns Hopkins University

Research defining a number of familial subtypes of bipolar disorder; founded Mood Disorders program at Johns Hopkins University.

1997 Arthur Prange, Jr., M.D.

University of North Carolina at Chapel Hill

Expert in endocrine function in psychiatric patients, which can be affected by psychiatric disorder as well as medications, for example antipsychotics.

Charles B. Nemeroff, M.D., Ph.D.

Emory University

Influential research aiming to uncover the neurobiology underlying increased risk for developing mood and anxiety disorders in child abuse victims, including early-life trauma.

1998 Martin B. Keller, M.D.

Brown University

Fundamental contributions to standardized, verifiable methods for assessing time to recovery, relapse, recurrence, and chronicity of episodes of mood and anxiety disorders. Developed the Longitudinal Interval Follow-Up Evaluation (LIFE).

Julien Mendlewicz, M.D., Ph.D.

University of Brussels/Erasmus Hospital, Belgium

Major contributions to the understanding of the physiopathology of affective disorders, particularly in the genetics of bipolar disorder.

FORMERLY KNOWN AS FALCONE PRIZE

1999 Frederick K. Goodwin, M.D.

George Washington University

Leading authority on bipolar disorder, as well as suicide and depression. Led research showing that lithium was significantly more effective than other widely used mood stabilizers in protecting against suicide.

Husseini K. Manji, M.D.

National Institute of Mental Health

Helped to conceptualize severe neuropsychiatric illnesses as genetically influenced disorders of synaptic and neural plasticity; investigated novel therapeutics including ketamine.

2000 Kay Redfield Jamison, Ph.D.

The Johns Hopkins University

Founded Affective Disorders Clinic at UCLA; influential author whose works include landmark text, "Manic-Depressive Illness" (with Dr. Fred Goodwin); and "An Unquiet Mind: A Memoir of Moods and Madness."

A. John Rush, Jr., M.D.

University of Texas Southwestern Medical Center at Dallas

Research focusing on treatments for depression and bipolar disorder, including medications, medication combinations, somatic treatments, psychotherapy, and disease management protocols.

Robert H. Belmaker, M.D.

Ben-Gurion University, Israel

A pioneer of biological psychiatry in Israel; research on affective disorders, especially mania; ECT; and second-messenger mechanisms.

2001 Hagop S. Akiskal, M.D.

University of California, San Diego

Renowned for his integrative theory of depression and research on subthreshold mood disorders, which enlarged conceptual boundaries of bipolar disorder; advanced the view that chronic depression is a treatable mood disorder.

William E. Bunney, Jr., M.D.

University of California, Irvine

Influential psychobiological studies of bipolar disorder, major depression, schizophrenia. Investigations of mechanisms of action of psychiatric medications.

COLVIN PRIZE

2002 Ronald Duman, Ph.D.

Yale University

Research characterizing the molecular and cellular actions of antidepressants and stress, providing the basis for a neurotrophic hypothesis of depression.

Paul Grof, M.D., Ph.D.

University of Ottawa, Canada

Helped develop Affective Disorder Clinics at Sunnybrook Medical Center, University of Toronto; performed research in psychobiology and helped establish a psychopharmacology research and training center.

2003 Robert M. A. Hirschfeld, M.D.

University of Texas Medical Branch, at Galveston

Research contributing to understanding the classifications of depression and bipolar disorders—their clinical course, relationship to personality and personality disorders and treatment.

Ross J. Baldessarini, M.D.

Harvard University

Psychopharmacology pioneer; studied pharmacology of neurotransmitters in bipolar disorder, discovering biochemical causes of high relapse risk following cessation of psychotropic medication.

Leonardo Tondo, M.D., M.S.

Cagliari University, Italy

Research on suicide prevention and on the course and treatment of bipolar disorders. Studies included clarification of onset, course, and treatment responses in major mood disorders.

2004 Harold A. Sackeim, Ph.D.

Columbia University

Authority on conduct and analysis of brain imaging studies; pioneering studies of cerebral blood flow and metabolism in depression, cerebrovascular disease and Alzheimer's disease.

Joseph R. Calabrese, M.D.

Case Western Reserve University School of Medicine

Authority on bipolar disorder, other mood disorders; influential research on clinical outcomes in people of under-served populations diagnosed with bipolar disorder.

2005 Jan A. Fawcett, M.D.

University of New Mexico

Research on and treatment of affective disorders and suicide prevention. Investigator in Recurrent Depression Prevention with Medication and Cognitive Behavioral Therapy project; co-founder of National Depressive and Manic-Depressive Association.

Alan F. Schatzberg, M.D.

Stanford University

Studied norepinephrine in depression as a means of subtyping cases; insights into the biological mechanisms underlying delusions in major depression; innovator in pharmacogenetics.

2006 Lori L. Altshuler, M.D.

University of California, Los Angeles

Advanced the understanding of fundamental mechanisms of mood dysregulation; first to identify amygdala activation levels relative to manic and depressive states in bipolar patients. Other findings helped differentiate bipolar disorder from schizophrenia and other psychotic disorders.

2007 Helen S. Mayberg, M.D.

Emory University

Influential imaging studies revealed functional abnormalities characterizing depression, as well as neural mechanisms mediating antidepressant response. Pioneered deep-brain stimulation for refractory depression.

2008 Charles L. Bowden, M.D.

University of Texas Health Science Center at San Antonio

Innovative research characterizing bipolar disorders and on the effectiveness and pharmacodynamics of mood-stabilizing drugs.

Mark S. George, M.D.

Medical University of South Carolina

Pioneered TMS, a non-invasive brain stimulation method, as a probe of mood-regulating neuronal circuits, conducting early clinical trials to treat refractory depression and leading to FDA approval in 2008.

2009 Lewis L. Judd, M.D., DSc (Hon.)

University of California, San Diego

Research centered on the course, recovery and outcome of mood and anxiety disorders and their management by psychopharmacologic medications.

Eric J. Nestler, M.D., Ph.D.

Mount Sinai School of Medicine

Influential research establishing that drug- and stress-induced changes in genetic transcription factors and chromatin remodeling mechanisms in reward pathways mediate long-lived behavioral changes relevant to addiction and depression.

FORMERLY KNOWN AS BIPOLAR MOOD DISORDERS PRIZE

2010 Lars Vedel Kessing, M.D., D.M.Sc.

Copenhagen University Hospital, Rigshospitalet, Denmark

Research on the onset, treatment and lifetime course of mood disorders; efficacy of medications in patients with mood disorders, particularly bipolar disorder.

2011 David J. Miklowitz, Ph.D.

University of California, Los Angeles

Research focusing on family environmental factors and family psychoeducational treatments for adult-onset and childhood-onset bipolar disorder.

Carlos A. Zarate, M.D.

National Institute of Mental Health

Pioneering studies that have led to novel fast-acting treatments for mood disorders such as depression and bipolar disorder; involved in pathbreaking ketamine research.

COLVIN PRIZE

COLVIN PRIZE

2012 **Eduard Vieta, M.D., Ph.D.**

University of Barcelona, Spain

Demonstrated efficacy of the most widely used atypical anti-psychotic—quetiapine—in monotherapy and combination therapy in the long-term prevention of manic and depressive episodes. Research indicating the acute and lasting effectiveness of psycho-education.

Karen Dineen Wagner, M.D., Ph.D.

University of Texas Medical Branch at Galveston

Influential research that has helped in the development and implementation of the most optimal approaches to childhood bipolar disorder.

2013 **Boris Birmaher, M.D.**

University of Pittsburgh School of Medicine

A leader in the study and treatment of pediatric mood and anxiety disorders; a pioneer in describing the course and treatment of childhood-onset bipolar disorder.

Andrew A. Nierenberg, M.D.

Harvard Medical School

Has directed the NIMH Bipolar Trials Network; helped establish concept of treatment-resistant depression; performed studies of children at risk for bipolar disorder and of the co-occurrence of bipolar disorder with ADHD.

2014 **Wayne C. Drevets, M.D.**

Johnson & Johnson, Inc.

Has led efforts to explore novel therapies and diagnostic approaches in depression and other mood disorders; recognized for his work in neuroimaging in psychiatry and functional neuroanatomical correlates of the normal and diseased brain.

Fritz A. Henn, M.D., Ph.D.

Cold Spring Harbor Laboratory, Ichan School of Medicine at Mount Sinai

Imaging, animal studies, and genetics to understand the bases of depression and schizophrenia. Has used animals modeling depression to identify genes altered by aversive experience.

2015 **Michael Berk, Ph.D., MBBCh, MMed, FF(Psych)SA, FRANCP**

Deakin University, Australia

Known for his discovery and implementation of novel therapies as well as studies of risk factors and biomarkers for a variety of psychiatric disorders.

L. Trevor Young, M.D., Ph.D., FRCPC

University of Toronto

Focused on understanding processes that lead to long-term changes in brain structure and function in patients with bipolar disorder and how these changes can be targeted by mood-stabilizing drugs.

2016 **Francis J. McMahon, M.D.**

National Institute of Mental Health

Characterizing genes involved in mood and anxiety disorders; also studies pharmacogenomics, including genetic studies of antidepressant outcomes, lithium response, and treatment-resistant depression.

Thomas G. Schulze, M.D.

Medical Center of the University of Munich, Germany

Researches genotype-phenotype relationships in psychiatric disorders; longitudinal psychosis research including study on the genetic basis of response to lithium treatment in bipolar disorder.

Pamela Sklar, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Influential discovery that schizophrenia is caused by genetic risk factors that overlap with those for bipolar disorder; identified the complex polygenic molecular nature of schizophrenia and bipolar disorder.

2017 **Hilary P. Blumberg, M.D.**

Yale University School of Medicine

Leader in research on bipolar disorder in children, adolescents, and adults. Important imaging demonstration of brain differences in individuals experiencing manic symptoms; scans comparing those with active depression and those in remission.

Tadafumi Kato, M.D., Ph.D.

RIKEN Brain Science Institute, Japan

Established role of mitochondrial dysfunction in bipolar disorder; developed animal model of spontaneous recurrent depression-like episodes that informs search for novel mood stabilizers.

Mary L. Phillips, M.D., M.D. (CANTAB)

University of Pittsburgh

Using neuroimaging techniques to discover functional and structural abnormalities in brain circuits for emotion processing and regulation and reward processing—useful in searching for biomarkers predicting psychiatric risk.

2018 **Benjamin I. Goldstein, M.D., Ph.D., FRCPC**

University of Toronto & Sunnybrook Health Sciences Center

Studies of bipolar disorder in youth; research that has led to a theory of bipolar disorder as a systemic vascular disease.

Lakshmi N. Yatham, M.B.B.S., FRCPC, M.R.C. Psych(UK), MBA(Exec)

University of British Columbia

A leader in neurocognition research in bipolar disorder; spearheaded development of a neurocognitive battery for assessing cognitive function; innovative clinical trial methodology to test the efficacy of treatments for improving cognition.

COLVIN PRIZE

2019 Dennis S. Charney, M.D.

Icahn School of Medicine at Mount Sinai

Played key role in fostering the discovery of the rapid anti-depressant effects of ketamine, the first fundamentally new depression pharmacotherapy mechanism in 60 years.

Sophia Frangou, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Has made groundbreaking contributions to the characterization of brain mechanisms of resilience in those at high familial risk for bipolar disorder.

John H. Krystal, M.D.

Yale School of Medicine

Played key role in fostering the discovery of the rapid anti-depressant effects of ketamine, the first fundamentally new depression pharmacotherapy mechanism in 60 years.

2020 Martin Alda, M.D., F.R.C.P.C.

Dalhousie University

Clinical, genetic, pharmacogenetic, and brain imaging studies based on carefully characterized prospective clinical samples, with goal of developing methods of personalized treatment in psychiatry.

Gustavo Turecki, M.D., Ph.D.

Douglas Institute, McGill University

Has contributed to our understanding of how traumatic life experiences impact gene function and increases long-term risk for suicide by regulating critical genes involved in stress response and behavioral development.

2021 Katherine E. Burdick, Ph.D.

Brigham and Women's Hospital, Harvard Medical School
Research on cognitive impairments in bipolar disorder, even during periods of remission, which contribute directly to functional disability.

Aleksander Mathé, M.D., Ph.D.

Karolinska Institute

Has investigated preclinical and clinical aspects of depression and PTSD pathophysiology and treatment mechanisms and has sought to develop novel treatments, including neuropeptide Y.

Colleen McClung, Ph.D.

University of Pittsburgh School of Medicine

Has advanced our understanding of the molecular basis of bipolar disorder, focusing on the role of circadian genes and central rhythm disruptions in the development and progression of this and other psychiatric diseases.

2022 J. John Mann, M.D.

Columbia University / New York State Psychiatric Institute

Has turned suicide prevention into a scientific endeavor. Identified serotonin-related abnormalities present in suicide attempters and clinical and biologic predictors of suicidal behavior in bipolar disorders.

2023 Roger S. McIntyre, M.D., FRCPC

University of Toronto, Canada

Characterizes the phenomenology and neurobiology of mood disorders and develops novel therapeutics. Especially interested in identifying innovative, rapid acting psychotropic treatments.

RUANE PRIZE

2000 Professor Sir Michael L. Rutter

King's College London, Institute of Psychiatry, UK

Contributed to the establishment of child psychiatry as a medical and biopsychosocial specialty with a strong scientific base.

2001 Donald J. Cohen, M.D.

Yale University

Helped move child psychiatry into the biological era, while continuing to put emphasis on the psychological and social aspects affecting child development.

2002 Judith L. Rapoport, M.D.

National Institute of Mental Health

Influential research on childhood-onset schizophrenia, ADHD, and OCD, with a particular focus on diagnosis. Influential genetic studies of psychiatric illness.

2003 Leon Eisenberg, M.D.

Harvard Medical School

Conducted some of the first rigorous studies of autism, ADHD, and learning delays and became a prominent advocate for children with disabilities.

2004 Magda Campbell, M.D.

New York University

Influential expert on pharmacology and adolescent disorders, including autism.

C. Keith Conners, Ph.D.

Duke University

Devised a 39-item questionnaire called the Conners Rating Scale that was part of clinical work with hyperactive children establishing the first standards for diagnosing and treating what is now known as ADHD.

Rachel G. Klein, Ph.D.

New York University

Influential childhood disorder research; showed that poor social adjustment in early childhood was an important negative predictor of the lifelong course of adults with schizophrenia; an expert on treatments for childhood disorders.

2005 Allan L. Reiss, M.D.

Stanford University

Uses neuroimaging, genetic analyses, neurocognitive assessment, and measurement of environmental factors to build models of brain function in individuals with typical and atypical learning and behavior.

RUANE PRIZE

2006 David A. Brent, M.D.

University of Pittsburgh School of Medicine

Co-founder of Services for Teens at Risk, a suicide prevention program. Research on suicide focusing on the epidemiology of adolescent suicide that has helped identify causal factors; worked to establish the role of cognitive therapy as a treatment for depressed adolescents.

David Shaffer, M.D.

Columbia University

Pioneer in the study of suicide; developed the widely adopted Children's Global Assessment Scale (C-GAS) and the Diagnostic Interview Schedule for Children (DISC) and the Columbia Teen Screen.

2007 James F. Leckman, M.D.

Yale University

Patient-oriented neuroscientist and clinician with special skills in the evaluation and treatment of Tourette's syndrome and pediatric-onset OCD; has studied ADHD, autism, and mood disorders.

2008 Eric Andrew Taylor, M.D.

King's College London, Institute of Psychiatry, UK

Has studied community screening for psychotic-like experiences and other potential antecedents of schizophrenia in children.

2009 Adrian C. Angold, M.D.

Duke University Medical Center

Applies developmental and epidemiological principles to the study of psychopathology. Research on depression, anxiety, and disruptive behavior disorders and their effects on service use in children and adolescents.

E. Jane Costello, Ph.D.

Duke University Medical Center

Leader of the Great Smoky Mountains Study, which demonstrated that anxiety disorders were not rare in a large community sample of children, viewed longitudinally.

2010 Terrie E. Moffitt, Ph.D.

Duke University

King's College London, Institute of Psychiatry, UK

Researches the interplay between nature and nurture in the origins of problem behaviors, with a particular interest in anti-social and criminal behaviors.

Avshalom Caspi, Ph.D.

Duke University

King's College London, Institute of Psychiatry, UK

Has studied how childhood experiences shape aging and health inequalities across the lifespan; how genetic differences shape the way people respond to their environments; devised ways to assess and measure personality differences between people.

2011 Daniel S. Pine, M.D.

National Institute of Mental Health

Studies biological and pharmacological aspects of mood, anxiety, and behavioral disorders in children; biological commonalities and differences among psychiatric disorders of children, adolescents, and adults; and interfaces between psychiatric and medical disorders.

2012 Daniel Geschwind, M.D., Ph.D.

University of California, Los Angeles

Takes a systems-biology approach, integrating genetic, genomic, and bioinformatic approaches with neurobiological investigation in model systems and human brain, aiming to inform development of new therapies.

Matthew State, M.D., Ph.D.

Yale University

Child psychiatrist and human geneticist studying pediatric neuropsychiatric syndromes; focuses on gene discovery as a launching point for efforts to illuminate the biology of disorders, including, notably, autism.

2013 Jay N. Giedd, M.D.

National Institute of Mental Health

Longitudinal studies combining brain imaging, genetics, and neuropsychology that have had a major impact on psychology, psychiatry, clinical care, the judicial system, parenting, adolescent medicine, substance abuse, and education reform.

2014 Anita Thapar, M.D., Ph.D.

Cardiff University School of Medicine, Wales

Has provided evidence suggesting existence of a spectrum of attention, hyperactivity/impulsiveness, and language function in society associated with clusters of genes linked with the risk for developing ADHD.

2015 BJ Casey, Ph.D.

Weill Cornell Medical College

Novel uses of brain imaging to understand childhood disorders; research focuses on the development of brain circuitry involved in learning and behavior regulation and how disruptions can lead to disorders.

Francisco Xavier Castellanos, M.D.

Child Study Center at NYU Langone Medical Center

Influential studies of ADHD using structural and functional imaging; collaborating on molecular genetic studies and coordinating the interdisciplinary ADHD Neuroscience Network, aiming at translation.

2016 John L. R. Rubenstein, M.D., Ph.D.

University of California, San Francisco

Demonstrated the role of specific genes in regulating neuronal specification, differentiation, migration, and axon growth during embryonic development and on through adult life—work that may help explain mechanisms underlying neurodevelopmental disorders such as autism.

2017 Nathan A. Fox, Ph.D.

University of Maryland, College Park

Research on the biological bases of social and emotional behavior; identified factors that reduce or enhance likelihood of anxiety; focuses mainly on cognitive processes.

Charles A. Nelson III, Ph.D.

Harvard Medical School

Researches problems in developmental cognitive neuroscience, including development of social perception; developmental trajectories to autism; effects of early adversity on brain and behavioral development; studied abandoned Romanian children.

RUANE PRIZE

Charles H. Zeanah, Jr., M.D.

Tulane University School of Medicine

Studies effects of adverse early experiences, including trauma, abuse, and neglect on young children's development. Has been a leader in infant mental health, exploring attachment and attachment disorders in conditions of extreme risk.

2018 Ami Klin, Ph.D.

Marcus Autism Center, Emory University School of Medicine & Children's Healthcare of Atlanta

Co-developer of eye-tracking technology; champion of notion that early detection and early intervention optimizes autism outcomes in children, beginning in the first year of life.

Joseph Piven, M.D.

University of North Carolina at Chapel Hill

Has emphasized interdisciplinary collaborations in imaging (MRI/DTI), behavioral-family, and molecular genetics studies aimed at elucidating the pathogenesis of autism syndromes. Principal investigator of two large-scale research centers on autism.

2019 Stephen P. Hinshaw, Ph.D.

University of California, San Francisco /

University of California, Berkeley

Has helped define fundamental features of ADHD, including details on clinical features as the disorder changes with development, aspects of underlying neurobiology, and approaches to treatment.

2020 Joan L. Luby, M.D.

Washington University School of Medicine, St. Louis

Has identified the clinical markers of depression in the pre-school period and has helped develop of a treatment designed to enhance emotion development as an early intervention for depression.

2021 Kenneth A. Dodge, Ph.D.

Duke University

Formulated a social information processing model of the development of aggressive behavior asserting that early adverse life events lead some children to develop a defensive mindset that leads to increasingly violent behavior.

John T. Walkup, M.D.

Northwestern University Feinberg School of Medicine

Johns Hopkins University

Influential research on movement disorders, specifically Tourette disorder, that uniquely spans psychiatry, child psychiatry, and neurology; interventions to reduce large mental health disparities among Native American youth.

2022 Boris Birmaher, M.D.

University of Pittsburgh Medical Center /

Western Psychiatric Institute

Leader in the study and treatment of pediatric mood and anxiety disorders. Described predictors, risk factors, course and treatment of childhood-onset bipolar disorder.

2023 Katie McLaughlin, Ph.D.

University of Oregon

Research on how environmental experience, especially adverse experience, influences brain and behavioral development in children and adolescents.

GOLDMAN-RAKIC PRIZE

2003 Solomon H. Snyder, M.D.

The Johns Hopkins University

Findings that permitted characterization of receptors in biochemical detail and have led to efficient means for identifying candidate drugs and for molecular structure-activity analysis to improve potency.

2004 Michael Posner, Ph.D.

University of Oregon

Pioneering PET imaging of the brain, revealing localization of cognitive functions by looking at the patterns of brain activation in progressively more complex cognitive tasks.

Marcus Raichle, M.D.

Washington University

Contributions to study of human brain function through development of PET and fMRI scanning. Landmark description of an integrated strategy for the design, execution, and interpretation of functional brain images.

2005 Bruce S. McEwen, Ph.D.

The Rockefeller University

Pathbreaking research elucidating the impact of stress and sex hormones on the brain's chemistry and structure, and revealing the brain's capacity for plasticity, even in adulthood.

2006 Joaquin M. Fuster, M.D., Ph.D.

University of California, Los Angeles

Major contributions to cognitive neuroscience, including demonstration that working-memory deficits are reversible.

2007 Huda Akil, Ph.D.

University of Michigan

Seminal contributions to the neurobiology of emotions, including pain, anxiety, depression, and substance abuse; elucidated role of endorphins in the brain, showing they are activated by stress and inhibit pain. Demonstrated that social defeat in rodents activates pathways like those altered in human depression.

GOLDMAN-RAKIC PRIZE

2008 Eric J. Nestler, M.D., Ph.D.

Mount Sinai School of Medicine

Pioneering studies of the molecular basis of addiction and depression in animal models, focusing on pathways that regulate responses to natural rewards such as food, sex, and social interaction.

2009 Brenda Milner, CC, Ph.D.

McGill University, Canada

Pioneer in understanding role of the frontal lobes in memory processing and organizing information, and which play a key role in emotional responses, hearing, memory, and speech. Identified the cortical area involved in the temporal organization of memory.

2010 Robert C. Malenka, M.D., Ph.D.

Stanford University

Seminal research on neurotransmitters that laid the groundwork for advanced understanding of mechanisms by which neurons communicate and adaptations in synaptic communication which underlie all behavior.

2011 Michael E. Goldberg, M.D.

Columbia University/New York State Psychiatric Institute

Discovered how the brain organizes visual attention and eye movements that are the overt manifestation of attention; how the brain creates a unitary concept of the visual world for perception and action despite a constantly moving eye.

2012 Larry R. Squire, Ph.D.

University of California, San Diego

Focuses on how the brain accomplishes learning and memory. Researches the function and organization of the brain systems that support memory, via cellular and molecular study of synaptic plasticity as well as the study of normal cognition.

2013 Karl Deisseroth, Ph.D.

Stanford University

Instrumental in developing optogenetics, the breakthrough technology that uses light to control millisecond-precision activity patterns in genetically-defined cell types within the brains of freely moving animals—a boon to researchers worldwide.

2014 Richard L. Huganir, Ph.D.

Johns Hopkins University School of Medicine

Research focusing on molecular mechanisms that modulate synaptic communication between neurons, with stress on mechanisms that underlie the regulation of glutamate receptors.

2015 Amy F. T. Arnsten, Ph.D.

Yale University

Research focusing on the prefrontal cortex; elucidation of molecular mechanisms that determine the strength of network connections and cognitive abilities; understanding how genetic insults lead to symptoms of mental illness.

2016 Earl K. Miller, Ph.D.

Massachusetts Institute of Technology

Studies neural basis of high-level cognitive functions, providing insights into how categories, concepts, and rules are learned, how attention is focused, and how the brain coordinates thought and action.

2017 Trevor W. Robbins, Ph.D.

University of Cambridge, UK

Studies the way dopamine, norepinephrine, serotonin, and acetylcholine mediate states such as mood and alertness; research on potential drug treatments for cognitive enhancement.

2018 Jean Pierre Changeux, Ph.D.

College de France & Institut Pasteur, France

Historic discovery of the mode of action of nicotine in the brain, its pharmacological receptors, and the molecular mechanism of its dual action: its therapeutic action as cognitive enhancer and its addictive properties as a drug of misuse.

Xiao-Jing Wang, Ph.D.

New York University

Has applied modeling to provide insights into the brain mechanisms of cognitive deficits associated with schizophrenia and other disorders, providing a foundation for the new field of computational psychiatry.

2019 René Hen, Ph.D.

Columbia University

Has demonstrated that antidepressants stimulate production of new neurons in the adult hippocampus and that this is required for some behavioral effects of antidepressants and for certain forms of learning.

2020 Robert Desimone, Ph.D.

Massachusetts Institute of Technology

Has shown that when we attend to something specific, neurons in the parts of the brain concerned with vision filter out distracting information, allowing us to concentrate on the task at hand.

Angela C. Roberts, Ph.D.

Girton College, University of Cambridge

Has revealed prefrontal cognitive processes underlying affective disorders and has elucidated the role of dopaminergic and serotonergic modulation of these processes essential for more effective therapeutic targeting.

2021 Elisabeth A. Murray, Ph.D.

National Institute of Mental Health

Research expanding our understand of how the primate prefrontal cortex and amygdala process feedback, produce decisions, and generate both autonomic and emotional responses.

György Buzsáki, M.D., Ph.D.

New York University

Introduced concept of feedforward inhibition and developed conceptual framework to understand fundamental synaptic mechanisms underlying brain rhythms, including theta, gamma, and sharp-wave ripple oscillations.

2022 Peter L. Strick, Ph.D.

University of Pittsburgh

Determined how each of the cortical motor areas differentially contributes to the generation and control of voluntary movement.

2023 Elizabeth A. Phelps, Ph.D.

Harvard University

Groundbreaking research on the neurobiology of human emotion, critically extending animal models of threat learning to the neural systems of anxiety and related disorders.

195 Scientific Council Members

- 47 Members of the National Academy of Medicine
- 45 Chairs of Psychiatry & Neuroscience Departments
- 14 National Institutes of Health Chiefs & Directors
- 7 Members of the National Academy of Sciences
- 3 Recipients of the National Medal of Science
- 1 Nobel Prize Winner

President

Judith M. Ford, Ph.D.

Vice President

John H. Krystal, M.D.

Ted Abel, Ph.D.

Anissa Abi-Dargham, M.D.

Nii A. Addy, Ph.D.

Susanne E. Ahmari, M.D., Ph.D.

Olusola Ajilore, M.D., Ph.D.

Schahram Akbarian, M.D., Ph.D.

Susan G. Amara, Ph.D.

Stewart A. Anderson, M.D.

Nancy C. Andreasen, M.D., Ph.D.

Carmen Andreescu, M.D.

Victoria Arango, Ph.D.

Amy F.T. Arnsten, Ph.D.

Gary S. Aston-Jones, Ph.D.

Randy P. Auerbach, Ph.D.

Tracy L. Bale, Ph.D.

Debra A. Bangasser, Ph.D.

Tallie Z. Baram, M.D., Ph.D.

Deanna M. Barch, Ph.D.

Samuel H. Barondes, M.D.

Carrie E. Bearden, Ph.D.

Francine M. Benes, M.D., Ph.D.

Karen F. Berman, M.D.

Wade H. Berrettini, M.D., Ph.D.

Randy D. Blakely, Ph.D.

Julie A. Blendy, Ph.D.

Pierre Blier, M.D., Ph.D.

Hilary P. Blumberg, M.D.

Vadim Bolshakov, Ph.D.

Kathleen T. Brady, M.D., Ph.D.

Kristen J. Brennand, Ph.D.

Robert W. Buchanan, M.D.

Peter F. Buckley, M.D.

William E. Bunney, Jr., M.D.

Joseph D. Buxbaum, Ph.D.

Tyrone D. Cannon, Ph.D.

William Carlezon, Ph.D.

William T. Carpenter, Jr., M.D.

Cameron S. Carter, M.D.

Edwin H. Cook, Jr., M.D.

Richard Coppola, D.Sc.

Christopher W. Cowan, Ph.D.

Ronald L. Cowan, M.D., Ph.D.

Joseph T. Coyle, M.D.

Jacqueline N. Crawley, Ph.D.

Kathryn R. Cullen, M.D.

Z. Jeff Daskalakis, M.D., Ph.D.

Karl Deisseroth, M.D., Ph.D.

J. Raymond DePaulo, Jr., M.D.

Robert Desimone, Ph.D.

Ariel Y. Deutch, Ph.D.

Ralph DiLeone, Ph.D.

Lisa Beth Dixon, M.D., M.P.H.

Wayne C. Drevets, M.D.

Kafui Dzirasa, M.D., Ph.D.

André Fenton, Ph.D.

Robert L. Findling, M.D., MBA

Cecilia Flores, Ph.D.

Stan B. Floresco, Ph.D.

Erika Forbes, Ph.D.

Alan Frazer, Ph.D.

Robert Freedman, M.D.

Aurelio Galli, Ph.D.

Mark S. George, M.D.

Elliot S. Gershon, M.D.

Mark A. Geyer, Ph.D.

Jay N. Giedd, M.D.

Jay A. Gingrich, M.D., Ph.D.

James M. Gold, Ph.D.

David Goldman, M.D.

Andrea Beth Goldschmidt, Ph.D.

Rita Z. Goldstein, Ph.D.

Joshua A. Gordon, M.D., Ph.D.

Elizabeth Gould, Ph.D.

Anthony A. Grace, Ph.D.

Dorothy E. Grice, M.D.

Raquel E. Gur, M.D., Ph.D.

Suzanne N. Haber, Ph.D.

Philip D. Harvey, Ph.D.

Stephan Heckers, M.D.

René Hen, Ph.D.

Takao K. Hensch, Ph.D.

Elliot Hong, M.D.

Laura Marianne Huckins, Ph.D.

Yasmin L. Hurd, Ph.D.

Robert B. Innis, M.D., Ph.D.

Alicia Izquierdo, Ph.D.

Jonathan A. Javitch, M.D., Ph.D.

Daniel C. Javitt, M.D., Ph.D.

Dilip V. Jeste, M.D.

Shafali Spurling Jeste, M.D.

René S. Kahn, M.D., Ph.D.

Ned H. Kalin, M.D.

Peter W. Kalivas, Ph.D.

Eric R. Kandel, M.D.

Thomas L. Kash, Ph.D.

Ege T. Kavalali, Ph.D.

Richard S.E. Keefe, Ph.D.

Christoph Kellendonk, Ph.D.

Martin B. Keller, M.D.

John R. Kelsoe, M.D.

Kenneth S. Kendler, M.D.

James L. Kennedy, M.D.

Robert M. Kessler, M.D.

Mazen Kheirbek, Ph.D.

Mary-Claire King, Ph.D.

Arnold Kriegstein, M.D., Ph.D.

Cecile D. Ladouceur, Ph.D.

Amanda J. Law, Ph.D.

James F. Leckman, M.D., Ph.D.

Ellen Lee, M.D.

Francis S. Lee, M.D., Ph.D.

Robert H. Lenox, M.D.

David A. Lewis, M.D.

Jeffrey A. Lieberman, M.D.

Gregory A. Light, Ph.D.

Kelvin O. Lim, M.D.

Sarah Hollingsworth Lisanby, M.D.

Daniel Lodge, Ph.D.

Joan L. Luby, M.D.

Irwin Lucki, Ph.D.

Beatriz Luna, Ph.D.

Gary Lynch, Ph.D.

Robert C. Malenka, M.D., Ph.D.

Anil K. Malhotra, M.D.

J. John Mann, M.D.

John S. March, M.D., M.P.H.

Stephen Maren, Ph.D.

Keri Martinowich, Ph.D.

Daniel H. Mathalon, Ph.D., M.D.

Helen S. Mayberg, M.D.

Carla A. Mazefsky, Ph.D.

Colleen A. McClung, Ph.D.

Ronald McKay, Ph.D.

James H. Meador-Woodruff, M.D.

Herbert Y. Meltzer, M.D.

Kathleen R. Merikangas, Ph.D.

Guo-Li Ming, M.D., Ph.D.

Karoly Mirnics, M.D., Ph.D.

Bitu Moghaddam, Ph.D.

Lisa M. Monteggia, Ph.D.

David A. Morilak, Ph.D.

Charles B. Nemeroff, M.D., Ph.D.

Eric J. Nestler, M.D., Ph.D.

Thomas Neylan, Ph.D.

Andrew A. Nierenberg, M.D.

Patricio O'Donnell, M.D., Ph.D.

Dost Ongur, M.D., Ph.D.

Maria A. Oquendo, M.D., Ph.D.

Martin P. Paulus, M.D.

Godfrey D. Pearson, M.D., Ph.D.

Peter Penzes, Ph.D.

Mary L. Phillips, M.D., M.D.

(CANTAB)

Marina R. Picciotto, Ph.D.

Daniel S. Pine, M.D.

Robert M. Post, M.D.

James B. Potash, M.D., M.P.H.

Susan Powell, Ph.D.

Pasko Rakic, M.D., Ph.D.

Perry F. Renshaw, M.D., Ph.D., M.B.A.

Kerry J. Ressler, M.D., Ph.D.

Victoria B. Risbrough, Ph.D.

Carolyn Rodriguez, M.D., Ph.D.

Bryan L. Roth, M.D., Ph.D.

Laura M. Rowland, Ph.D.

Scott J. Russo, Ph.D.

Gerard Sanacora, M.D., Ph.D.

Akira Sawa, M.D., Ph.D.

Alan F. Schatzberg, M.D.

Nina R. Schooler, Ph.D.

Robert Schwarcz, Ph.D.

Yvette I. Sheline, M.D.

David A. Silbersweig, M.D.

Vikaas S. Sohal, M.D., Ph.D.

Matthew W. State, M.D., Ph.D.

Murray B. Stein, M.D., M.P.H.,

F.R.C.F.C.

Joanna C. Steinglass, M.D.

Stephen M. Strakowski, M.D.

Carol A. Tamminga, M.D.

Laurence H. Tecott, M.D., Ph.D.

Flora M. Vaccarino, M.D., Ph.D.

Rita J. Valentino, Ph.D.

Jeremy M. Veenstra-VandeWeele, M.D.

Susan M. Vogelmaier, M.D., Ph.D.

Aristotle N. Voineskos, M.D., Ph.D.

Nora D. Volkow, M.D.

Karen Dineen Wagner, M.D., Ph.D.

Daniel R. Weinberger, M.D.

Myrna M. Weissman, Ph.D.

Rachel Yehuda, Ph.D.,

Jared W. Young, Ph.D.

L. Trevor Young, M.D., Ph.D.,

F.R.C.P.C., F.C.A.H.S.

Carlos A. Zarate, Jr., M.D.

Jon-Kar Zubieta, M.D., Ph.D.



The Board of Directors of the Brain & Behavior Research Foundation
Congratulates the

2024 BBRF Outstanding Achievement Prizewinners

Pardes Humanitarian Award Prizewinner,
Franca Ma-ih Sulem Yong

&

the Honorary Pardes Humanitarian Award recipient,
The Graham Boeckh Foundation

*“If you want to have good ideas,
you must have many ideas.”*

– Linus Pauling

*“Research is seeing what everybody else
has seen, and thinking what nobody else
has thought.”*

– Albert Szent-Györgyi

Congratulations to this year’s award winners for their
outstanding scientific achievements.

We celebrate Brain & Behavior Research Foundation’s
37 years of leadership and support
of mental health research.



The Lieber and Simon families

In Honor of the
2024 Pardes Humanitarian Prize in Mental Health Recipient
&
Honorary Pardes Humanitarian Prize
In Mental Health Recipient

You have inspired us all to
use our knowledge towards the greater good for all humanity.

With deep respect,
The Pardes Humanitarian Prize Committee

J Squared Press

Printers of Brochures,
Catalogs and Fine Lithography



Would Like to Congratulate
The Brain & Behavior Research Foundation
and the **2024 Awardees**

We extend our heartfelt congratulations to the 2024 Outstanding Achievement Prizewinners and Pardes Humanitarian Prizewinners. Your exceptional contributions continue to advance our understanding of mental health and inspire innovative treatments.

The Columbia University Department of Psychiatry is proud to support the Brain & Behavior Research Foundation and celebrate your remarkable achievements.



GBF develops large-scale, collaborative initiatives that aim to transform mental health care systems across Canada, including partnerships with governments to develop a new model of easily accessible mental health care for young people aged 12–25.

Known as **Integrated Youth Services**, the model is rapidly scaling up in diverse communities.

See: <https://grahamboeckhfoundation.org>

We are proud to support BBRF and extend sincere congratulations to the 2024 Award Recipients!



In honor of the Lieber Family's commitment to the importance of mental health research, Alpine Saxon Woods, LLC celebrates the 2024 Pardes Humanitarian Prize winners and the distinguished scientists who are the recipients of the Brain & Behavior Research Foundation Outstanding Achievement Prizes.

Asset Management • Hedge Funds • Separately Managed Accounts

Alpine Saxon Woods, LLC • www.AlpineSaxonWoods.com • (914) 251-0880

Congratulations
to the
2024 Pardes Humanitarian Prizewinner
FRANCA MA-IH SULEM YONG
and
2024 Pardes Humanitarian Honorary
Prizewinner
THE GRAHAM BOECKH
FOUNDATION
and to all the
Outstanding Achievement
Prizewinners

Milton and Tamar Maltz

BY THE NUMBERS SINCE 1987

As of August 2024

AWARDED TO SCIENTISTS



\$461+ MILLION

GRANTS

6,500



GRANTEES

5,600



UNIVERSITIES & MEDICAL CENTERS

605



COUNTRIES, INCLUDING THE U.S.

41



195 ACTIVE SCIENTIFIC COUNCIL MEMBERS

The all-volunteer BBRF Scientific Council is composed of leading experts across disciplines in brain & behavior research who review grant applications and recommend the most promising ideas to fund.

The group includes:

- 47 Members of the National Academy of Medicine
- 45 Chairs of Psychiatry & Neuroscience Departments
- 14 National Institutes of Health Chiefs & Directors
- 7 Members of the National Academy of Sciences
- 3 Recipients of the National Medal of Science
- 1 Nobel Prize Winner



**BRAIN &
BEHAVIOR**

RESEARCH FOUNDATION

Awarding **NARSAD** Grants

100% OF EVERY DOLLAR
DONATED FOR RESEARCH
GOES TO RESEARCH

747 Third Avenue, 33rd Floor New York, NY 10017
800.829.8289 | bbrfoundation.org



Awarding **NARSAD** Grants

The Brain & Behavior Research Foundation is committed to alleviating the suffering caused by mental illness by awarding grants that will lead to advances and breakthroughs in scientific research.

747 Third Avenue, 33rd Floor, New York, NY 10017 | 646.681.4888 | bbrfoundation.org